Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;92(6):E114-E117.
doi: 10.1002/ajh.24720. Epub 2017 Apr 18.

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

Nicholas J Short  1 , Hagop M Kantarjian  2 , Heidi Ko  3 , Joseph D Khoury  4 , Farhad Ravandi  2 , Deborah A Thomas  2 , Guillermo Garcia-Manero  2 , Maria Khouri  2 , Jorge E Cortes  2 , William G Wierda  2 , Srdan Verstovsek  2 , Zeev Estrov  2 , Alessandra Ferrajoli  2 , Philip A Thompson  2 , Sherry Pierce  2 , Susan M O'Brien  5 , Elias Jabbour  2
Affiliations

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

Nicholas J Short et al. Am J Hematol. 2017 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest: The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Survival of patients with relapsed/refractory Burkitt or high-grade B-cell leukemia or lymphoma. A) Overall survival measured from time of first treatment failure (N=35) and B) Relapse-free survival measured from time of second remission (N=11). C) Overall survival of patients with refractory disease or early relapse (initial remission duration <6 months) versus late relapse (initial remission duration ≥6 months). D) Overall survival of patients who responded to salvage chemotherapy versus those who did not respond.
See this image and copyright information in PMC

References

    1. Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. The oncologist. 2006;11:375–383. - PubMed
    1. Thomas DA, O’Brien S, Faderl S, et al. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Current hematologic malignancy reports. 2011;6:58–66. - PMC - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. - PMC - PubMed
    1. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580. - PubMed
    1. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–2411. - PubMed

Publication types

MeSH terms